DOP2020000212A - ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS - Google Patents

ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS

Info

Publication number
DOP2020000212A
DOP2020000212A DO2020000212A DO2020000212A DOP2020000212A DO P2020000212 A DOP2020000212 A DO P2020000212A DO 2020000212 A DO2020000212 A DO 2020000212A DO 2020000212 A DO2020000212 A DO 2020000212A DO P2020000212 A DOP2020000212 A DO P2020000212A
Authority
DO
Dominican Republic
Prior art keywords
rur20kd
related compositions
compositions
selective treg
treg stimulator
Prior art date
Application number
DO2020000212A
Other languages
English (en)
Inventor
Benedict Kirk Peter
Zalevesky Jonathan
L Langowski John
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of DOP2020000212A publication Critical patent/DOP2020000212A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación proporciona composiciones de estimulador de Treg selectivo, que incluyen RUR20kD-IL-2 y composiciones relacionadas, y métodos de uso de estas composiciones, por ejemplo, para tratar enfermedades autoinmunitarias y/u otras afecciones que responden al tratamiento que es eficaz para proporcionar un aumento de las cantidades y la activación de los linfocitos T reguladores sobre los linfocitos T efectores.
DO2020000212A 2018-05-21 2020-11-19 ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS DOP2020000212A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862674244P 2018-05-21 2018-05-21
PCT/US2019/033100 WO2019226538A1 (en) 2018-05-21 2019-05-20 SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS

Publications (1)

Publication Number Publication Date
DOP2020000212A true DOP2020000212A (es) 2021-03-15

Family

ID=67002369

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000212A DOP2020000212A (es) 2018-05-21 2020-11-19 ESTIMULADOR DE TREG SELECTIVO RUR20kD-IL-2 Y COMPOSICIONES RELACIONADAS

Country Status (19)

Country Link
US (1) US20210205413A1 (es)
EP (1) EP3796940A1 (es)
JP (2) JP7235772B2 (es)
KR (1) KR20210002577A (es)
CN (1) CN112399859A (es)
AU (2) AU2019274409B2 (es)
BR (1) BR112020021564A2 (es)
CA (1) CA3100204A1 (es)
CL (1) CL2020003008A1 (es)
CO (1) CO2020014510A2 (es)
CR (1) CR20200546A (es)
DO (1) DOP2020000212A (es)
EA (1) EA202092489A1 (es)
EC (1) ECSP20074392A (es)
JO (1) JOP20200290A1 (es)
PE (1) PE20211307A1 (es)
PH (1) PH12020551976A1 (es)
SG (1) SG11202011242SA (es)
WO (1) WO2019226538A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023514010A (ja) 2020-01-10 2023-04-05 ブライト ピーク セラピューティクス エージー 修飾ｉｌ－２ポリペプチドおよびその使用
CN113121671A (zh) * 2020-01-15 2021-07-16 天津键凯科技有限公司 一种制备结合位点可控的peg化生物分子的方法
CN113121670B (zh) * 2020-01-15 2022-11-22 天津键凯科技有限公司 二取代peg化白细胞介素2及其制备方法、应用
US20230272001A1 (en) * 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
WO2022109477A1 (en) * 2020-11-23 2022-05-27 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
AU2022414070A1 (en) 2021-12-14 2024-05-16 Eli Lilly And Company Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401756A (en) 1981-04-14 1983-08-30 Immunex Corporation Process for preparing human interleukin 2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5153310A (en) 1989-02-28 1992-10-06 Du Pont Merck Pharmaceutical Company Il-2 analogs containing n-linked glycosylation sites
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
FR2826365B1 (fr) 2001-06-20 2003-09-26 Oreal Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile
EA011351B1 (ru) 2003-05-23 2009-02-27 Нектар Терапеутикс Ал, Корпорейшн Полимерные реагенты, способы их получения, а также содержащие их конъюгаты и фармацевтические препараты
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US7567215B1 (en) 2007-10-23 2009-07-28 The United States Of America As Represented By The Secretary Of The Navy Portable and inflatable antenna device
KR20230148396A (ko) 2010-11-12 2023-10-24 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
CN103732241A (zh) 2011-03-11 2014-04-16 公共事业救济局-巴黎医院 低剂量il-2用于治疗自身免疫相关病症或炎性病症的应用
JP6911044B2 (ja) 2016-03-16 2021-07-28 シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ

Also Published As

Publication number Publication date
CA3100204A1 (en) 2019-11-28
JOP20200290A1 (ar) 2020-11-15
KR20210002577A (ko) 2021-01-08
CR20200546A (es) 2021-05-18
JP2021523922A (ja) 2021-09-09
PH12020551976A1 (en) 2021-09-13
BR112020021564A2 (pt) 2021-03-02
EA202092489A1 (ru) 2021-03-16
SG11202011242SA (en) 2020-12-30
US20210205413A1 (en) 2021-07-08
WO2019226538A1 (en) 2019-11-28
CN112399859A (zh) 2021-02-23
PE20211307A1 (es) 2021-07-20
EP3796940A1 (en) 2021-03-31
CL2020003008A1 (es) 2021-07-30
AU2022246440A1 (en) 2022-11-03
ECSP20074392A (es) 2021-03-31
AU2019274409B2 (en) 2022-07-14
JP7235772B2 (ja) 2023-03-08
AU2019274409A1 (en) 2020-11-12
JP2023052053A (ja) 2023-04-11
CO2020014510A2 (es) 2021-03-08

Similar Documents

Publication Publication Date Title
CO2020014510A2 (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2018003213A1 (es) Inhibidores enzimáticos.
ES2692773T3 (es) Tratamientos para la fibrosis
CL2020002161A1 (es) Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano.
CO2019006902A2 (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus
UY36741A (es) Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
BR112019005944A2 (pt) anticorpos que se ligam à interleucina 2 e usos dos mesmos
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
BR112017007813A2 (pt) composições oftalmológicas, método de prevenção, redução ou tratamento de transtornos causados por olhos secos e uso de ciclosporina e trealose
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
ECSP20082339A (es) Moduladores de la expresión de apol1
CL2018003214A1 (es) Composiciones cosméticas prebióticas y uso de las composiciones cosméticas prebióticas
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
BR112019021300A8 (pt) Composições de fragrâncias e produtos com efeitos de melhora do humor
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
AR117094A1 (es) Moduladores de expresión irf5
CO2022009433A2 (es) Uso de isatuximab para el tratamiento del mieloma múltiple recidivante y/o refractario
CL2021000928A1 (es) Composiciones y métodos para la estimulación ovárica controlada
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
AR120038A1 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
CO2022003324A2 (es) Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares